REVB · Revelation Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $4.06M | $3.55M | $4.15M | $6.91M | - | - |
| SG&A | $5.01M | $4.43M | $4.51M | $5.49M | $3.09M | $145.5K |
| Total Operating Expenses | $9.07M | $7.98M | $8.66M | $10.86M | $3.09M | $145.5K |
| D&A | $27.1K | $27.9K | $25.0K | $25.0K | - | - |
| Operating Income | ($9.07M) | ($7.98M) | ($8.66M) | ($11.95M) | - | ($136.4K) |
| Interest Expense | - | - | - | - | $41.8K | - |
| Income Tax | $0 | $0 | $0 | $0 | - | - |
| Net Income | ($8.91M) | ($15.04M) | ($120.3K) | ($10.83M) | ($2.13M) | ($136.4K) |
| EPS - Basic | ($23.95) | ($1052.16) | ($101.76) | ($115718.40) | ($137088.00) | - |
| EPS - Diluted | ($23.95) | ($1052.16) | ($101.76) | ($244800.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.70M | $6.50M | $11.99M | $5.25M | $78.5K | $11.7K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $577.5K | $783.6K | $1.36M | $554.2K | $784.8K | - |
| Current Assets | $10.81M | $6.57M | $12.15M | $5.41M | $83.4K | $651.3K |
| Total Assets | $11.58M | $6.62M | $12.21M | $5.50M | $48.39M | $74.16M |
| Current Liabilities | $2.00M | $1.91M | $5.56M | $4.45M | $5.49M | $33.8K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.72M | $1.91M | $5.56M | $4.45M | $8.40M | $2.95M |
| Stockholders' Equity | $8.86M | $4.71M | $6.65M | $1.05M | ($7.82M) | $5.00M |
| Retained Earnings | ($49.42M) | ($40.51M) | ($25.47M) | ($25.35M) | ($7.82M) | ($140.0K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.27M) | ($18.32M) | ($7.29M) | ($11.22M) | ($725.6K) | ($218.7K) |
| Investing Cash Flow | - | ($19.2K) | - | - | $25.74M | ($74.04M) |
| Financing Cash Flow | $12.47M | $12.85M | $14.03M | $15.20M | ($24.95M) | $74.27M |
| CapEx | - | $19.2K | - | $132.0K | - | - |
| Free Cash Flow | - | ($18.34M) | - | ($11.35M) | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | 1.22 | - | 1.05 | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -77.0% | -227.1% | -1.0% | -196.8% | -4.4% | -0.2% |
| Return on equity | -100.6% | -319.4% | -1.8% | -1029.0% | 27.2% | -2.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.02 | 19.28 |
| Quick ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.02 | 19.28 |
| Cash ratio | 5.36 | 3.40 | 2.15 | 1.18 | 0.01 | 0.35 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.41 | 1.84 | 5.23 | -6.19 | 14.83 |
| Liabilities / Assets | 0.23 | 0.29 | 0.46 | 0.81 | 0.17 | 0.04 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.2x | 3.2x | 99.3x | 10264.7x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.7% | 7.9% | 27.6% | - | - | - |
| Net income growth (YoY) | 40.7% | -12405.6% | 98.9% | -408.3% | -1462.0% | - |
| EPS growth (YoY) | 97.7% | -934.0% | 100.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 88.2% | -29.2% | 531.6% | - | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing REVELATION BIOSCIENCES against the 5 most active filers in the same SIC group.